<SEC-DOCUMENT>0001493152-26-024715.txt : 20260521
<SEC-HEADER>0001493152-26-024715.hdr.sgml : 20260521
<ACCEPTANCE-DATETIME>20260521063815
ACCESSION NUMBER:		0001493152-26-024715
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260521
DATE AS OF CHANGE:		20260521

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immix Biopharma, Inc.
		CENTRAL INDEX KEY:			0001873835
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				454869378
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-292665
		FILM NUMBER:		261005839

	BUSINESS ADDRESS:	
		STREET 1:		11400 WEST OLYMPIC BLVD.
		STREET 2:		SUITE 200
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90064
		BUSINESS PHONE:		(888) 958-1084

	MAIL ADDRESS:	
		STREET 1:		10573 W. PICO BLVD.
		STREET 2:		#58
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90064

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immix Biopharma, Inc.
		CENTRAL INDEX KEY:			0001873835
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				454869378
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		11400 WEST OLYMPIC BLVD.
		STREET 2:		SUITE 200
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90064
		BUSINESS PHONE:		(888) 958-1084

	MAIL ADDRESS:	
		STREET 1:		10573 W. PICO BLVD.
		STREET 2:		#58
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90064
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>formfwp.htm
<DESCRIPTION>FWP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
Pursuant to Rule 433 under the Securities Act of 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuer
Free Writing Prospectus dated May 21, 2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Statement No. 333-292665</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="formfwp_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 21, 2026, the Company issued a press release announcing the pricing of a $150 million underwritten offering
of common stock. A copy of the press release is attached hereto as Appendix A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Company has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates.
Before you invest, you should read the prospectus in the registration statement, as well as the other documents the Company has filed
with the SEC for more complete information about the Company and this offering. You may get these documents, and the prospectus supplement,
when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the Company, or any underwriter participating
in the offering will arrange to send you the prospectus if you request it by contacting: Morgan Stanley &amp; Co. LLC, Attention: Prospectus
Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone: 1-866-718-1649, or email: <U>prospectus@morganstanley.com</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Appendix
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immix
Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LOS
ANGELES, CA, May 21, 2026 (GLOBE NEWSWIRE) &mdash; Immix Biopharma, Inc. (&ldquo;ImmixBio&rdquo;, &ldquo;Company&rdquo;, &ldquo;We&rdquo;
or &ldquo;Us&rdquo; or &ldquo;IMMX&rdquo;), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered
offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The gross proceeds to Immix
from the offering, before deducting the underwriting discounts, commissions and other offering expenses, are expected to be $150
million. The offering is expected to close on or about May 22, 2026, subject to the satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immix
intends to use the net proceeds from this offering to fund NXC-201 development, working capital and general corporate purposes. Immix
believes that the net proceeds from the offering, together with its existing cash and cash equivalents, will be sufficient to meet the
Company&rsquo;s operational needs into mid-2028.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan
Stanley is acting as the lead book-running manager and BofA Securities is acting as book-running manager for the offering. LifeSci Capital, Mizuho and Needham &amp; Company are acting as co-lead managers for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities in the registered offering are being offered and sold pursuant to a &ldquo;shelf&rdquo; registration statement on Form S-3
(File No. 333-292665), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on
January 9, 2026, and declared effective on January 22, 2026. A prospectus supplement and accompanying prospectus describing the terms
of the registered offering will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the prospectus supplement
and the accompanying prospectus relating to the offering, when available, may also be obtained from: Morgan Stanley &amp; Co. LLC, attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone: 1-866-718-1649 or by email: <U>prospectus@morganstanley.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor
shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Immix Biopharma, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immix
Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune
system, that&rsquo;s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ
failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201
with a &ldquo;digital filter&rdquo; that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize
and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory
AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation
(BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward
Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements within the meaning of the federal securities laws. Words such as &ldquo;may,&rdquo;
&ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;predict,&rdquo; &ldquo;forecast,&rdquo; &ldquo;project,&rdquo; &ldquo;plan,&rdquo;
&ldquo;intend&rdquo; or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements.
These forward-looking statements are based upon current estimates and assumptions and include statements relating to the offering, including
the timing of the closing of the offering, the anticipated use of proceeds therefrom, the Company&rsquo;s cash runway, the potential
benefits of the Company&rsquo;s product candidate CAR-T NXC-201 and the timing and results related to clinical trials, including
planned trials. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any
such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements
are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially
from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could
cause actual results to differ materially from current expectations include, among others, risks and uncertainties relating to market
conditions; the completion of the proposed offering on the anticipated terms or at all; the risk that the estimates for the number of
patients in the U.S. with relapsed/refractory AL Amyloidosis and the market size are not accurate; the risk that further data from the
ongoing U.S. Phase 1b/2 clinical trial and ex-U.S. Phase 1b/2a clinical trial for CAR-T NXC-201 will not be favorably consistent with
the data readouts to date; that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated
into a commercial drug product; that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials
will be successful; and those other risks disclosed in the section &ldquo;Risk Factors&rdquo; included in the Company&rsquo;s Annual
Report on Form 10-K for the fiscal year ended December 31, 2025 and other periodic or current reports subsequently filed with the Securities
and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors
is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does
not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated
events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that
we will make additional updates with respect to those or other forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts</B><BR>
<BR></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mike
Moyer<BR>
LifeSci Advisors<BR>
mmoyer@lifesciadvisors.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Contact<BR>
<BR>
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">irteam@immixbio.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>formfwp_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formfwp_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !. 0P# 2(  A$! Q$!_\0
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M;&6.3UKRK2_VB_BSKFHC3M.U%KS4&)7[/%9H7##J,5]WZO\ \@J\_P"N#_\
MH)KX!_9F_P"2^:(>YN+K/O\ *] 'T]^SEK_Q!UU->;QW;W-N8I(ULA<0+$2N
M#NQCKVKUCQ%/+:Z%J,\+>7-%;22(^ <,%)%:?:LKQ-_R+>K_ /7G-_Z : /@
ML?M3?$Y49AKL6Y<XB^RISCMD^M?:_P +/&L?Q"\$:/KJ$;KF!?.0<;)1]\8^
MM?"7P4\"Q_$;7-<T5T#S2:9.]NQ_@E'W2/QKUK]BWX@3:7K>I>"M3=D:?]];
MH_!25  Z?I^E 'V)(,J> >.]>-_M,_%B[^%_@B)])F2+6K^41P$J&P!RQP?;
M->OD[UR!G(X%?$WQ)O)?C]^T?:^'[)S+I5C,+-2/NA$!,\G_ ++0!7^'O[1O
MQ#UOQYX>TV_UN*:QNKV.*5! B[EZD9%?;[XC!V_+R>/;/6OSQ\-V,.G?M$V=
MI;(J6EOK[0QCV5B :_1+^-O\]Z /GG]JKXJ^*/ALGAH^'M02P:]:43%X!(&*
MC(ZUQ7P _:2\2:_\0[31O%>H1WEEJ"&*%EA">7/U0?B*O?MTG]QX1XS\\_'_
M  &O&O&/@R?PYX$\ ^-M*!MVNXMDDW_/*ZC=BC_\"48H _15>*1_RKCOA7XW
MA^(G@+1M>A(#3PJ)E/5)!PZG\:R_CI\0O^%=?#+5]51]E[(AM[,-WE?Y5_+K
M0!\X?%W]IWQ9;?$35['PQJ<5IHMH_P!GB(A5][K]]OF_VJ]C_96^(7B'XC^%
MM8OO$5T+VZ@NQ%$XC5/EV#^[7RM!X!-O\#=0\8WJ$W-_J<5I:L_]P%C+)_P)
MJ^AOV'./ WB+L/[0_P#9!4R=@/H#5F>+3+UXQB1(BRMC<=V#CBOEWX:?$KQU
MJWQ TJRU#4+R2PEG994>VVK@=!G;7U5<.$@+$X5068^V*\Y\,_&CP?XB\2+H
ME@9&U'<R*WD;1N4X;FOF<VI*>)HMU_9Z[?S>1[N5U'##U4J'M+K?^7S/0YXY
M7M'B@;[/*4(1P VTXX.#7QMK7Q[^)'PO^(K:3XCU%;^RL[M#<QFV5'FMR>'0
M^F#^E?:L; J.=Q]Z\"_:P^$;^,_#"^)-+@#ZUI*,611S/;_Q)]1UKZ57TUT/
M 76[N>YZ'JUMKNDV>HV<HFM;J-98W!!!!&<<>G2KCD[@ 0/7/7%?)'['/Q9%
ML7\#ZA*4B<F;3'<_=XRT7UZUZQ^T?\5Q\,O!#I9RJNNZGFWLO6/CYI#[ 591
MY#\</VE_$47Q _L#P)<1Q) PMF?RP_FW!.-OX5]*?#NWUVP\(:>GB6\.HZRT
M8>XE6,(%8C.W ]*^7?V0OA!)KVK/XUU:,R65HY6R2<<SS9RTQ]@3Q7V9&20?
MK0!Y%\6OC#-X,NXM+TN**74602.TY^55/;ZU2^&'QQF\3:XNCZO;Q6]Q.6%O
M)"3@D#D'/>L?XY?#K5;O7EUK3;22^MKA/+N(XAEU9?ND>@K&^#WPUUNZ\4VN
MJZC:S:?86!+ W"X>:0^GI]:_)JF+SA9VHI>[M;[/+W'([WXR?&)?AK!!:V=M
M'=:G<H6CCF;"H,\DUX5K/[0WC/Q+MLXIXK)IW" 6ZE6.3@<GVKTC]I'X9ZMX
MDNK/6=+LWO/(@,,MM& 6ZYW>]?/"6%_X:U&UN[JPO+412JY,L)7(#=<GBO'X
MAQ^:4\>Z;<E2NK6[=3]BX;R_**F7JK-1=:ST;Z]#ZILUTOX#^!+6XCM?M6JW
M; RR$[I+F8C)WL>U<[H'[1NHC581JMA;-8/)MD> G=%D^G>ND^).C-\4/A]I
M.IZ&PGGA"SHJ$,'&.17CVB_#CQ#XAU2*RCTFXMMS#?).N%B4')YKT,PQ6:83
M'4:>71_=M*W9I[W/R?$2<JDO;?%=GT]XN\;VGA/PI-K3 S1!0T:]W)&0!7BM
MI^TAKB:@D]S9V[63$%K<'#JI[YKU#XC> I?$OP[31[.0-=VJ(T?^TRC&/QKY
MWMOAUXFU"]-E_8]VL[L$9G7:B@]3FNS/,7G%+%T8X6/NNU['+J?7N@ZI%K>F
M6U] 28;A!(N>P-:(K%\&Z*/#OARQTW(+6T01B#GGO6T._P!:_3,,Y.C%SWL(
MJ:O_ ,@J\_ZX/_Z":^ OV9/^2]:)_P!?%U_Z"]??NK_\@J\_ZX/_ .@FO@+]
MF3_DO6B?]?%U_P"@O72!^@X^[67XF_Y%S5_^O.;_ - -:@^[67XF_P"1<U?_
M *\YO_0#0!\2_L<8_P"%QGU%E,1Z=>?TJ;]H/P_<?!WXX6WB?2T:*VO9A?Q%
M.!Y@QYJ<>O)Q[U%^QN2/C&V.<V4V17T3^T[\.SX[^&U[);@?VII7^F6I R2%
MSO7\5_D* +?Q(^,-CH/P6N?%]E+EKVS4V>.IED&U0/=3DGZ5YG^Q3X D@TW4
M_&=^NZYO<VEJS#DH#ND?_@3=_:OG/3M;U_Q]I'ACP):R--:)?%K5!G(=^#N_
MV5&?QK]%/!WABT\&^&M-T6R39;V, A4^N!R?J30!\%Z+_P G*0?]C$__ *&U
M?H@/OG_/>OSNT/G]I&'_ +&23_T)J_1#^(_Y[T ?*/[=!VP^$#_MS_\ H-=)
MX0\ I\1OV1M/T4\W7V(RVS'DB9"67]17,?MU_P"H\(C_ &Y__0:]@_9KR/@=
MX7*C+>2V/^^FH \._8S\=OH^O:GX)OV,8N&:XM YP5D7B1#[U7_:G\1W7Q'^
M)^C> ]);SXK21 P0\&Z?C)'<*M8'Q_\ #EW\(/CA;>)-&'D17DW]I6S#A!*!
MAT^AYXKJ?V2?"UUXV\>Z[\0=5C,GER.L)89W3O\ >(]@.!0!UG[4'ABU\(?L
M]Z-HEJ (+*YMH ?4J&R3[D\T?L.?\B/XB_Z_Q_Z *UOVT4V_"*#WU*'^35D_
ML.?\B/XB_P"O\?\ H I,74^BK\?Z%-_N-_(U\:_!(D_&G3P22//GZ_\  J^R
MK_\ X\IO]QOY&OC3X(_\EIL/^N\__LU?F_$VN98+_&??<-?\B_'_ .#]3[1/
M!...:0HKQD,NY3P01G.>"*5OO'ZTY.4]<8[XK]&CT/@%NSX(^/WP\O?@O\28
M=5TMGATR>;[;87*?\L9=V7B./4\_2J$MWXB_:>^*VGQ3QF(O"JMMY6UMUX<_
M5CS^-=O^UQ\34\8^*K+P7I*BXMM/G5[B6,;FEN&X6-#^/-<-\)O&=]\"/BL%
MUFW:SMW86>JP2#+1JW*NOXD9JRC[V\,^'[/PQH=GI5A"(;2UC$<:XZ@#J?K6
MO@>E5[.>*[M8IX9%EBE4.LB'(8'H:L#I0!Y]\0?BKIO@#R;>2%KO49E^6WB/
M('O6?\//C3IGCG4/[.>WDT_4=I:.&8\.O?\ &O,?VA/#-_9>+?[5$4S6%Q$J
MK,@SL<=5^AK(^#/AF_UWQQ9W4$4B6=K(6FGP0$(_A&>U?D]3-\SCG2PRI^[M
M;IR][CN>]_$'XD:?\/[&-[E&FO;@GRK56VLV*X[PW\7=$\?7B:/K&B):R71\
MN,S8DC;(Y!/8UD?M%^&[Z6]L=<@B>XLH8RDCQKN,9SVKSCX?^&-0\1^*]/@M
M+>58HIUDN)MI41*.F*689KF4<VCA52O#:UKIKU-HR4-8NS.B\6ZGK?[.?BDP
M:.1/X9OSYL-G.Y/DMW53Z5N>%_VJ++4-1@M=7TLZ;#<.$^TI)E58]FK)_:QU
M2UFN]$T\.LUS 'D;#@%<\#CO7A^C>'=1\3:G!I^G6DEQ/,RJ<(0JCNQKP\=F
MV.RW-'A<#)N%UI:]K[I/H?K^7Y3@,RRN.)QT4I6=Y7L]-F?>6M>)=/T'0Y-5
MO)0EI$N\.?XACC;7EUA^TIIUSJ(2?3)X+)F4+<%N<'H2*U?BCX-U#4OA5;Z?
M:+]INK)(W:/.2^P $"OF^*PNM2N1:VUO--?3_NQ;^6003U!^E?1Y[FN987%4
M84:>CL?CDTHR<8['W'8W4=Y;)/"X>*0;E8=P:L XKGO .CS:#X0TRPN"?.@A
M"L"<X/I6ZY^8#KGCCJ/>OT;"SG4HPG-6;1!!K#?\2J^_Z]Y/_037P%^S3E/C
M[H8[&>Z_]!>O:OC3^TUX@\!>.-6\-6>@P7MI'" )W#[CN'.,#!KYK\">+M0^
M'GC6W\26FFR7=S 9)$MYHW"#?G...P)KK0'Z8AQP*S?$_P#R+FK_ /7G-_Z
M:\L_9Z^-&J?%XZ\^I:7%IO\ 9\D:1B,,"^X').?I7J/B1PWAS50>,VLH^OR&
MF!\3?L;?\EF_[<IZ^YY8DDB=&0,C!E*^H/45\.?L<P31_&1S+;S0[;.?ED(
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M(G'>-J(OB<AK/)86^?9SC'I6UM"3U#X9_$*#XD^&!K%I;/9PM(T2QOUR._\
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%'S?,_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
